Get Started Free
Home›Technology›Danaher Corporation
Danaher Corporation logo
Danaher Corporation
Technology

Danaher Corporation Company Overview

Danaher Corporation logo

Danaher Corporation

● Active
Technology · Washington, DC · Est. 1969
Life SciencesDiagnosticsBiotechnologyIndustrial TechnologyHealthcare↗ Website
$172.0B
Valuation
$25.5B
Revenue
65k+
Employees
1969
Founded

Danaher is a global science and technology innovator that designs, manufactures, and markets professional, medical, industrial, and commercial products and services. Operating through its Biotechnology, Life Sciences, and Diagnostics segments, Danaher serves researchers, clinicians, and industrial scientists with instruments, consumables, and software critical to drug discovery, clinical diagnostics, and environmental testing.

Recent Press
5 items
Acquisition·2026-02-15
Danaher Announces $9.9B Acquisition of Masimo Corporation
Danaher agreed to acquire Masimo Corporation for $180 per share in cash, totaling approximately $9.9 billion, expecting Masimo to generate over $530 million EBITDA in 2027 and deliver $125 million in annual cost synergies within five years.
Press Release·2026-01-28
Danaher Guides 2026 Core Revenue Growth of 3-6% with EPS of $8.35-$8.50
Danaher issued 2026 full-year guidance for non-GAAP core revenue growth of 3% to 6% year-over-year and adjusted diluted net EPS of $8.35 to $8.50, reflecting continued recovery in life sciences end markets and bioprocessing demand.
Press Release·2026-01-28
Danaher Reports Full-Year 2025 Revenue of $24.6B, Up 3% Year-Over-Year
Danaher reported full-year 2025 revenues of $24.6 billion, up 3.0% year-over-year, with non-GAAP adjusted diluted EPS of $7.80, up 4.5%, and generated $5.3 billion in free cash flow for the year.
Press Release·2026-01-28
Danaher Q4 2025 Revenue Rises 4.5% to $6.8B with $1.8B Free Cash Flow
Danaher posted Q4 2025 revenue of $6.8 billion, up 4.5% year-over-year, with operating cash flow of $2.1 billion and non-GAAP free cash flow of $1.8 billion, as adjusted diluted EPS grew 4.0% to $2.23.
Press Release·2025-10-20
Danaher Life Sciences Segment Returns to Growth as Bioprocessing Demand Recovers
Danaher's life sciences segment returned to positive organic revenue growth in H2 2025 as bioprocessing customer inventory destocking ended, with biopharma companies resuming capital investments in manufacturing capacity.
Company History
10 milestones
Danaher was founded in 1969 as a real estate investment trust in Washington, DC, before transforming into an industrial holding company under brothers Steven and Mitchell Rales in the mid-1980s, who redirected the company into manufacturing and science.

Danaher Corporation Organization Structure & Team

Org Chart
65,000 employees · Click a leader to explore their team
59,700 across 12 departments
Chief Executive Officer
Rainer Blair
Matt McGrew — Departments
· 59700 people across 12 depts

Danaher Corporation Financials, Revenue & Market Share

Annual Revenue
$25.5B
+7% vs prior year
YoY Growth
+7%
From $29.5B to $25.5B
Revenue / Employee
$368K
Annual revenue per full-time employee
Revenue Growth
2021
2022
2023
2024
2025
$29.5B
$31.5B
$23.9B
$23.9B
$25.5B
Market Share
Bioprocessing Equipment and Consumables
25%
share
Danaher
25%
Sartorius
18%
Thermo Fisher Scientific
22%
Merck KGaA (MilliporeSigma)
15%
Others
20%
$280B
TAM
$95B
SAM
$23.9B
SOM
Revenue Streams
Biotechnology34%
Life Sciences32%
Diagnostics34%
Business Units
Biotechnology (Cytiva + Pall)34%
Cytiva provides bioprocessing instruments and single-use technologies for biopharmaceutical manufacturing; Pall Life Sciences provides filtration and separation systems used across drug substance and drug product manufacturing.
Life Sciences (Leica, SCIEX, Beckman Coulter LS, Abcam)32%
Provides analytical instruments, imaging systems, mass spectrometry, and protein research reagents to academic, pharmaceutical, and biotechnology research customers for drug discovery and basic research.
Diagnostics (Beckman Coulter Diagnostics, Cepheid, Radiometer)34%
Supplies clinical laboratory analyzers and reagents for routine and specialized hospital testing, including chemistry, immunoassay, molecular diagnostics, and blood gas analysis across hospital and reference laboratory settings.

Danaher Corporation Internal Tools & Processes

Internal Tools
12 departments
Cytiva — Bioprocessing9500 people · 3 roles
Standards & Certifications
10 standards
Compliance frameworks, security audits, and quality certifications this company maintains.
Quality
ISO 13485:2016
Certified
Danaher's medical device and in vitro diagnostic manufacturing businesses — including Beckman Coulter, Cepheid, and Radiometer — maintain ISO 13485:2016 certification, ensuring that quality management systems for clinical analyzer design, manufacturing, and post-market surveillance meet global medical device quality requirements.
Quality
ISO 9001:2015
Certified
Danaher's life science instrument and bioprocessing manufacturing facilities globally maintain ISO 9001:2015 quality management certification, covering Cytiva bioreactor systems, Leica Microsystems optical instruments, and SCIEX mass spectrometry platforms.
Regulatory
FDA 21 CFR Part 820
Compliant
Danaher's US-based IVD and medical device businesses, including Beckman Coulter Diagnostics and Cepheid, comply with FDA Quality System Regulation (21 CFR Part 820), governing design controls, manufacturing quality systems, and post-market surveillance for clinical laboratory instruments.
Regulatory
EU IVDR 2017/746
Compliant
Danaher's Beckman Coulter Diagnostics and Cepheid have transitioned their European IVD portfolios to comply with EU In Vitro Diagnostic Regulation (IVDR) 2017/746, including updated performance evaluation reports, notified body certification for high-risk assays, and EUDAMED registration.
Regulatory
GMP 21 CFR Part 211
Compliant
Cytiva and Pall Life Sciences comply with FDA 21 CFR Part 211 cGMP requirements for components, containers, and closures used in biopharmaceutical drug manufacturing, as their single-use bioprocess systems are directly used in FDA-regulated drug production.
Environmental
ISO 14001:2015
Certified
Danaher's major manufacturing sites maintain ISO 14001:2015 environmental management certification, supporting the company's sustainability commitments including a goal to reduce absolute Scope 1 and Scope 2 greenhouse gas emissions by 50% by 2035.
Security
SOC 2 Type II
Certified
Danaher's cloud-connected instrument platforms — including Cepheid OnDemand, Beckman Coulter Remote Analytics, and Cytiva Bioprocess Cloud — are SOC 2 Type II certified, protecting customer laboratory and manufacturing data transmitted to Danaher cloud platforms.
Regulatory
CLIA Compliance
Compliant
Beckman Coulter Diagnostics and Cepheid IVD systems sold in the US are cleared or approved under CLIA (Clinical Laboratory Improvement Amendments) for use in waived, moderate, and high-complexity laboratory settings, enabling placement across the full hospital laboratory continuum.
Regulatory
FCPA Compliance
Compliant
Danaher operates a global Foreign Corrupt Practices Act compliance program governing its commercial relationships with government hospital customers, tender processes, and distributor arrangements in markets across Asia, the Middle East, and Latin America where public health system sales are common.
Environmental
REACH and RoHS
Compliant
Danaher's laboratory instruments and analytical equipment sold in the European Union comply with REACH chemical substance restrictions and RoHS directives governing hazardous substances in electrical and electronic equipment, including Leica microscopes, SCIEX mass spectrometers, and Beckman Coulter analyzers.

Danaher Corporation Interview Preparation

Interview Prep
Role-specific interview questions and keywords. Select a department, then click any role to prepare.
Cytiva — Bioprocessing· 3 roles

Danaher Corporation Products & Competitors

Product Suite
5 products · select one to explore
Technology
Life Sciences Instrument
Cytiva ÄKTA pure
The gold standard in protein purification chromatography

ÄKTA pure is a benchtop liquid chromatography system designed for research and process development in biopharmaceutical manufacturing. It automates column-based protein purification workflows — from initial capture to polishing — with reproducible results across ion exchange, affinity, and size-exclusion modes.

Use Cases
Running affinity chromatography purifications of monoclonal antibodies for preclinical studiesDeveloping and transferring protein purification methods from research scale to GMP manufacturingExecuting multi-step polishing runs using SEC and IEX columns on the same automated platform
No image
Key Customers
DNA
Genentech
AZN
AstraZeneca
PFE
Pfizer
Competitive Intelligence
VSBio-Rad NGC System
THEM

Bio-Rad's NGC Chromatography System is a modular FPLC platform offering gradient mixing, UV/conductivity detection, and fraction collection for protein purification in research and bioprocess development labs.

EDGE

Deeper integration with Cytiva resins and columns gives ÄKTA pure a validated end-to-end purification workflow advantage

VSKnauer AZURA
THEM

Knauer's AZURA FPLC system is a European-made liquid chromatography platform for biomolecule purification, offering modular pump and detector configurations for research labs.

EDGE

ÄKTA pure's UNICORN software provides superior method transfer and FDA 21 CFR Part 11 compliance for regulated biopharma environments

VSRepligen OPUS
THEM

Repligen's OPUS pre-packed column systems pair with third-party FPLC instruments to provide ready-to-use chromatography solutions for bioprocess scale-up.

EDGE

Integrated hardware and software on a single validated platform reduces qualification burden versus column-only solutions